A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients

A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients

Serum lactate dehydrogenase (LDH) is a standard prognostic biomarker for stage IV melanoma patients. Often, LDH levels do not provide real-time information about the metastatic melanoma patients’ disease status and treatment response. Therefore, there is a need to find reliable blood biomarkers for...

Full description

Bibliographic Details
Main Authors: Matias A. Bustos, Rebecca Gross, Negin Rahimzadeh, Hunter Cole, Linh T. Tran, Kevin D. Tran, Ling Takeshima, Stacey L. Stern, Steven O’Day, Dave S. B. Hoon
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
serum LDH
blood biomarker
miRNA
circulating microRNA
plasma
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/12/11/3361

Similar Items

Similar Items